Physician profile
Lawrence Edo Abah
NPI 1306305115
$12,083.41
in general payments reported to CMS, 2019-2025
22 companies · $3,266 in 2025
The $3,266 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $837 · 2022: $1,847 · 2023: $3,381 · 2024: $2,752 · 2025: $3,266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,298 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,297.54 |
| Education | $101.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,403.24 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,517.17 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $1,430.15 | 2021-2025 | Spravato, Invega Sustenna |
| Corium, LLC | $1,018.56 | 2022-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,010.24 | 2021-2025 | Caplyta |
| Alkermes, INC. | $809.48 | 2022-2025 | Lybalvi, Aristada |
| Lundbeck LLC | $754.17 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $719.22 | 2022-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $629.82 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $472.37 | 2021-2025 | Austedo Xr |
| Tris Pharma INC | $279.18 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Supernus Pharmaceuticals, INC. | $278.82 | 2022-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $260.43 | 2022-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $140.51 | 2025 | Fanapt |
| Noven Therapeutics, LLC | $84.12 | 2024-2025 | Xelstrym |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $71.14 | 2024-2025 | Cobenfy |
| Neuronetics, INC. | $69.41 | 2023 | Neurostar Tms Therapy System |
| Neurocrine Biosciences, INC. | $49.95 | 2023-2025 | Ingrezza |
| Novo Nordisk INC | $23.63 | 2024 | Ozempic, Rybelsus |
| Idorsia Pharmaceuticals US INC | $23.55 | 2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $23.14 | 2025 | Jornay Pm |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.11 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Abah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.